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Poly(ADP-ribose) polymerases (PARPs) catalyze
poly(ADP-ribose) addition onto proteins, an impor-
tant posttranslational modification involved in tran-
scription, DNA damage repair, and stem cell identity.
Previous studies established the activation of PARP1
in response to DNA damage, but little is known about
PARP1 regulation outside of DNA repair. We devel-
oped an assay for measuring PARP activity in cell
lysates and found that the basal activity of PARP1
was highly variable across breast cancer cell lines,
independent of DNA damage. Sucrose gradient frac-
tionation demonstrated that PARP1 existed in at
least three biochemically distinct states in both
high- and low-activity lines. A discovered complex
containing the NuA4 chromatin-remodeling complex
and PARP1 was responsible for high basal PARP1
activity, and NuA4 subunits were required for this ac-
tivity. These findings present a pathway for PARP1
activation and a direct link between PARP1 and
chromatin remodeling outside of the DNA damage
response.
INTRODUCTION
Poly(ADP-ribose) (PAR) is a reversible posttranslational modifi-
cation involved in multiple essential cellular processes including
DNA damage, transcriptional control, and stem cell identity
(Beneke, 2012; Chiou et al., 2013; Doege et al., 2012; Hassa
and Hottiger, 2008; Ji and Tulin, 2010; Krishnakumar and
Kraus, 2010a; Ogino et al., 2007; Tallis et al., 2014). Using nico-
tinamide adenine dinucleotide (NAD+) as a substrate, poly(ADP-
ribose) polymerases (PARPs) polymerize ADP-ribose subunits
onto acceptor proteins, forming large, negatively charged poly-
mers of varying length (Schreiber et al., 2006; Tan et al., 2012).
Polymers can be quickly hydrolyzed by poly(ADP-ribose) glyco-
hydrolases (PARGs), leading to turnover of the NAD+ pool (Die-
fenbach and Bu¨rkle, 2005; Hassa and Hottiger, 2008). Covalent
attachment of PAR to a protein (PARylation) can alter its func-
tion. PARP1, for example, loses its PARP activity upon automo-1808 Cell Reports 8, 1808–1818, September 25, 2014 ª2014 The Audification (Ferro and Olivera, 1982; Zahradka and Ebisuzaki,
1982). Alternatively, PAR can serve as a scaffolding molecule,
recruiting downstream PAR-binding effectors (Sousa et al.,
2012). Seventeen putative PARPs have been identified in hu-
mans, based on sequence homology (Schreiber et al., 2006),
but not all possess PARP activity (Kleine et al., 2008).
PARP1, localized primarily to the nucleus, is the most abundant
family member in humans (Vyas et al., 2013; Wang et al., 2012)
and has been mainly examined in the context of base excision
repair (Sousa et al., 2012). Recently PARP1 was implicated in
other DNA repair pathways as well as in pathways outside of
DNA repair such as transcription (Ji and Tulin, 2013; Krishnaku-
mar and Kraus, 2010b) and stem cell identity (Chiou et al.,
2013; Doege et al., 2012; Ogino et al., 2007). The details of
its involvement in any of these pathways remain poorly
understood.
There is much interest in the use of PARP inhibitors as can-
cer therapeutics. At least six phase III trials are ongoing or
being planned for PARP1 inhibitors (Garber, 2013). These
trials focus mainly on targeting cancers with defects in ho-
mologous recombination in an effort to exploit the hypothesis
that PARP1 inhibition is synthetically lethal with other DNA
repair defects (Farmer et al., 2005; Javle and Curtin, 2011).
However, the role of PARP1 in DNA damage does not fully
explain the efficacy of PARP inhibitors (Audeh et al., 2010;
Garnett et al., 2012; Lord and Ashworth, 2013). To better un-
derstand the utility of PARP inhibitors in the clinic, we must
better understand the function and regulation of PARPs in
cancer, especially PARP1, the common target of all the clinical
candidates.
Despite their clinical as well as basic biological importance,
fundamental questions about the regulation and cellular func-
tions of PARPs remain unanswered. To explore potential rolls
outside of the DNA damage response, we investigated basal
PARP activity across breast cancer cell lines and found, unex-
pectedly, large variation due to differences in basal PARP1 acti-
vation states and not in gene expression or protein abundance.
Our findings provide a pathway for PARP1 activation and sug-
gest that PARP1 exists in different biochemical states both
within a single cell line as well as between cell lines. Our find-
ings further the basic understanding of PARP1 biochemistry
and suggest roles for PARP1 outside of the DNA damage
response.thors
Figure 1. Basal PARP Activity Varies across
Cell Lines
(A) As a proxy for PARP activity, PARaccumulation
in lysates was measured across the breast cancer
cell lines indicated. PAR levels were normalized by
total protein in the lysates. Error bars show SE
and nR 6.
(B) PARP activity in lysates was measured with
32P-NAD+ addition to lysates plus 1 mMADP-HPD.
Data were fit with a one-step binding curve. Error
bars show SD and n = 5. a.u., arbitrary units.
(C) PAR degradation rates were measured by
incubating prelabeled 32P-PAR-PARP1 with ly-
sates plus 10 mM ABT-888. Data were fit with a
one-step decay curve. Error bars show SD and
n = 5. The decay rate is not significantly different
for the two data sets; p = 0.26 (calculated using
Prism).
See also Figure S1.RESULTS
Basal PARP1 Activity Varies Strongly across Breast
Cancer Cell Lines
To profile basal activation states of PARP, we measured PARP
activity in cell lysates, in the absence of DNA damage, across
a panel of breast-cancer-derived cell lines. We used a bead-
based capture assay optimized for lysate measurements that
allowed for better quantification of PAR levels than the stan-
dard immunoblot-based assay. Our assay is complimentary to
a recent mass spectrometry method quantifying steady-state
PAR levels in cells or tissues (Martello et al., 2013). Lysates
were prepared from cells grown under standard, nonstressed
growth conditions. A PARG inhibitor, ADP-HPD, was added to
the lysis buffer to prevent degradation of PAR during the assay,
which was important because PAR degraded quickly in its
absence. PAR was captured onto beads coated with an anti-
PAR monoclonal antibody and detected using a tandem zinc-
finger PAR-binding domain from the protein APLF (Ahel et al.,
2008). PAR, produced and purified in vitro (Tan et al., 2012),
was used as a standard. Addition of a PARP inhibitor directly
to the lysis buffer confirmed that the assay measures PAR accu-
mulation in lysates, but not preformed PAR from cells, because
most of the detectable PAR accumulated after lysate prepara-
tion (Figure S1). Thus, the assay measures total PARP activity
in lysate, not cellular PAR levels.
We found a surprising degree of variation in total PARP activity
across 11 breast cancer cell line lysates, with up to 60-fold vari-
ation, using the assay (Figure 1A). Differences in polymer levels
were also seen by immunoblot for PAR, a standard assay in
the field (Figure S1). We were unable to detect a PARP-depen-
dent signal by immunofluorescence (data not shown), confirmingCell Reports 8, 1808–1818, Septhat our assay measures accumulation of
PAR in the lysates and not basal levels.
We further validated this result using a
radioactive polymerization assay. Cell ly-
sates from MCF7 (high activity) or T47D
(low activity) cells were incubated with
32P-NAD+ in the presence of ADP-HPD,and the rate of PAR synthesis was measured using a filter-bind-
ing assay. Synthesis rates weremuch higher inMCF7 cell lysates
(Figure 1B). The rate of PAR degradation was measured by add-
ing preformed 32P-labeled PAR to lysates in the presence of
ABT-888 to block further synthesis. MCF7 and T47D cell lysates
showed similar rates of PAR degradation (Figure 1C). We
concluded that the basal activity of one or more PARPs is differ-
entially regulated between MCF7 and T47D cells, whereas the
rates of PAR degradation do not vary significantly in the two lines
tested.
To determine which PARP family members are activated in
MCF7 cells, we measured PARP activity in cell lysates from cells
treated either with the PARP1–PARP4 inhibitor ABT-888 or
the PARP5a/PARP5b inhibitor XAV939 (Wahlberg et al., 2012).
XAV939 also binds PARP1/PARP2 but with approximately
10-fold lower affinity than to PARP5a/PARP5b (Huang et al.,
2009a; Wahlberg et al., 2012). Across the cell lines tested,
PARP activity was reduced by >97% in the presence of ABT-
888, whereas XAV939 reduced PARP activity by 30%–70% (Fig-
ure 2A). We further narrowed the possibilities with a PARP1/
PARP2-specific inhibitor, niraparib (Jones et al., 2009), which
reduced activity by 95% (Figure S2A). Of PARP1 and PARP2,
PARP1, due to its high abundance, was the most obvious candi-
date. Using small interfering RNA (siRNA), we knocked down
PARP1 in two cell lines with high PARP activity, KPL-1 and
MCF7. In both cell lines, PARP1 knockdown of 70%–90% (Fig-
ure 2B) resulted in an approximately 80% loss in lysate PARP
activity (Figure 2C). We confirmed by RT-PCR that PARP1 siRNA
was specific to PARP1 and did not affect PARP2 RNA levels (Fig-
ure S2B). These data indicate that PARP1 is the primary enzyme
responsible for the high basal PARP activity in the tested cell
lines.tember 25, 2014 ª2014 The Authors 1809
Figure 2. Differences in PARP Activity Result from PARP1 Activation
(A) Cells were treated with DMSO (purple), 10 mM ABT-888 (yellow), or 10 mM
XAV939 (green) for 2 hr, and PAR accumulation in the lysates was measured.
Total PAR is normalized by total protein in the lysates. Error bars show SE with
n = 6.
(B) PARP1 knockdown in MCF7 and KPL-1 cells with lamin A/lamin C siRNA
(Dharmacon) as a control.
(C) For PARP1 activity, control siRNA (solid bars) and PARP1 siRNA
(open bars) lysates with equal amounts of total protein were incubated with
32P-NAD+ for 30 min. A representative experiment from three independent
experiments is shown.
(D) PARP1 protein levels across the cell lines shown. Bands were quantified
using ImageJ, and PARP1 protein levels were normalized by tubulin levels.
See also Figure S2.
1810 Cell Reports 8, 1808–1818, September 25, 2014 ª2014 The AuPARP1 activity could be regulated at either the mRNA or pro-
tein level. We compared PARP1 transcript levels across cell lines
using published data (Neve et al., 2006). The small differences in
transcript levels found seemed unlikely to account for the activity
differences (data not shown). We then measured protein levels
using immunoblots. Indeed, PARP1 protein levels were relatively
constant across cell lines (Figure 2D), and the small differences
observed did not correlate with differences in PARP1 activity.
Instead, the results are consistent with the enzymatic activity
of PARP1 being regulated through mechanisms other than tran-
scription, translation, or degradation.
PARP1 Activation Is Independent of DNA Strand Breaks
Based on the literature, our initial hypothesis was that PARP1 is
basally activated in some cancer cell lines due to spontaneous
DNA damage. To test this hypothesis, we measured DNA dam-
age using phospho-histone H2Ax, which forms foci at the sights
of DNA strand breaks, as a marker. Immunofluorescence mea-
surements of phospho-H2Ax in fixed cells, grown under stan-
dard conditions in the absence of DNA-damaging agents,
showed faint staining in most lines and much stronger staining
following treatment with neocarzinostatin, an inducer of strand
breaks. No significant correlation between basal phospho-
H2Ax staining and basal PARP activity was found (Figures
S3A–S3C). We also measured the levels of phospho-ATM,
ATR, Chk1, and Chk2 as other markers for activation of the
DNA damage-repair pathways. We saw very little activation of
these proteins in the absence of a DNA-damaging agent (Fig-
ure S3D). We concluded that spontaneous DNA damage does
not explain the differences in basal activation of PARP1 in these
cell lines.
Another possible explanation is that DNA was released during
lysate preparation and its presence activated PARP1 in lysates.
To test this, we blotted for histones in either the lysate superna-
tant or pellet. We found 70%–80% of total PARP1 in the super-
natant and no histone H4. Histone H4 was only found in the
pellet (Figure S4A), indicating that the active PARP1 we were
measuring was nucleoplasmic and not tightly bound to chro-
matin. It also suggested that no or very little chromatin was pre-
sent in our lysate preparations. To further test for the presence
of DNA, the DNA-binding dye YOYO-1 was added to control
lysates and lysates treated with DNase I. YOYO-1 fluoresces
upon binding to nucleic acids and detects picograms of DNA.
We observed weak signal in untreated lysates corresponding
to 1 to 2 pg of nucleic acid/ng of total protein (0.1% of the total
protein). This signal was the same for both MCF7 and T47D ly-
sates. The signal remained after DNase I treatment of the lysates
(Figure S4B). We also ran precleared and cleared lysate samples
treated with RNase on agarose gels and stained for nucleic acids
with SYBR Safe (Invitrogen; Figure S4C). We saw no staining in
the cleared lysate samples, indicating that DNA was removed
from the lysates upon centrifugation. Based on the limits of
detection in our YOYO-1 assay, these experiments show that
there is less than 0.02 pg of DNA/ng of protein in the lysate.
The DNase-resistant YOYO-1 signal may result from binding to
RNA in the lysates. Even if a small amount of DNA is present, it
appears to be the same for the two samples and cannot account
for the differences in PARP activity.thors
Figure 3. PARP1 Is Found in Multiple
Biochemical States
MCF7 (A, C, E, and G) and T47D (B, D, F, and H)
lysates were fractionated using 5%–40% sucrose
gradients.
(A and B) Aliquots from each fraction were incu-
bated with 32P-NAD+ for 30 min in the absence
(solid dark gray line) and presence (light gray line)
of 10 mM ABT-888.
(C and D) Aliquots from the same sucrose gradient
fractions were used for PARP1 immunoblots.
(E and F) PARP1 activity from (A) and (B) was
normalized by PARP1 protein levels to give spe-
cific activity. Representative data from two inde-
pendent experiments is shown.
(G and H) Aliquots from each fraction were incu-
bated in the absence (solid line) or presence
(dashed line) of 0.02 mg/ml nicked DNA. Specific
activity was determined as in (E) and (F).
See also Figure S4.PARP1 Is Found in Multiple Biochemically
Distinct Complexes
As an unbiased approach to characterizing cell line differ-
ences, we fractionated cell lysates using sucrose gradients
and measured PARP activity and PARP1 protein levels across
fractions. The PARP activity of each fraction was measured in
the presence and absence of ABT-888 to confirm specificity of
NAD+ incorporation (Figures 3A and 3B). The distribution of
PARP1 protein between fractions was similar in both high- and
low-activity lines (Figures 3C and 3D). Approximately 44% was
found in a fraction whose mobility was that expected of uncom-
plexed PARP1 sedimenting as amonomer or dimer. The sucrose
gradient cannot distinguish between a monomer and a dimer,
but previous studies have shown that PARP1 functions as a
dimer (Mendoza-Alvarez and Alvarez-Gonzalez, 1993; Pion
et al., 2005). Approximately 10% of PARP1 protein was found
in an 700 kD region and 35% in a high-molecular-weight
region (>1 MD). The distribution of PARP1 protein was similar
in both cell lines.
Basal PARP1 activity was detected by 32P-NAD+ polymeriza-
tion. Activity in the uncomplexed PARP1 was undetectable. In
MCF7 (high activity) lysates, PARP1 activity was strong in the
700 kD and >1 MD fractions. We compared activity to protein
levels measured by immunoblot to estimate specific activity inCell Reports 8, 1808–1818, Separbitrary units and found the highest
specific activity in the 700 kD fraction
(Figures 3E and 3F). This fraction was
responsible for most (75%) of the
increased basal PARP1 activity in MCF7
cells as compared to T47D cells.
To determine if PARP1 activity could
be increased, we added nicked DNA
to each fraction and remeasured the
PARP1 activity (Figures 3G and 3H). We
found that even the most active
PARP1-containing fractions could be
further activated with the addition of
nicked DNA. Both the 700 kD and >1MD fractions were activated to approximately the same level
of specific activity. The uncomplexed fraction showed some in-
crease in activity but was the least activated in the presence
of DNA. Taken together, the fractionation data indicate that
PARP1 exists in at least three separate forms, each with a
distinct basal activation state and potential for activation by
nicked DNA. The difference in PARP activity between the two
cell lines derives mainly from different basal activation states
of the 700 kD fraction.
PARP1 with High Basal Activity Is in Complex with NuA4
To find candidate binding partners, fractions 2+3, 6, and 9+10
from an MCF7 lysate sucrose gradient were immunoprecipi-
tated with anti-PARP1, and coprecipitating proteins were iden-
tified via tandem mass spectrometry of tryptic peptides (liquid
chromatography-tandem mass spectrometry [LC-MS/MS]).
Spectral counts of PARP1 peptides across the three fractions
correlated well with the abundance of PARP1 protein measured
by immunoblotting (Tables 1 and S1; Figure 3C), showing quan-
titative recovery of PARP1 protein. We detected no significant
binding partners in the uncomplexed fraction. We were particu-
larly interested in fraction 6, given its high basal PARP activity
in MCF7 (high activity) cells as compared to T47D (low activity)
cells. Enrichment analysis was performed on the top 50tember 25, 2014 ª2014 The Authors 1811
Table 1. Active PARP1 Coimmunoprecipitates with Components
of the NuA4 Complex
Sucrose Gradient SILAC
Spectral Counts per Fraction ln (MCF7/T47D Ratio)
Gene Name 2+3 6 9+10 Average
PARP1 147 27 47 0
TRRAP 93 6
EP400 6 69 4 0.63 ± 0.34
RUVBL1 31 7 0.64 ± 0.074
RUVBL2 28 10
EPC1 19 1.9 ± 0.17
ACTL6A 13 4 1.1 ± 0.092
DMAP1 13 1 1.2 ± 0.15
BRD8 10 1 0.93 ± 0.42
YEATS4 7 2
ING3 5
VPS72 5 1 0.81 ± 0.25
KAT5 3 1.8 ± 0.18
MORF4L1 2 1 1.1 ± 0.16
MORF4L2 2
PARP1 was immunoprecipitated from the indicated sucrose gradient
fractions (sucrose gradient) or total lysates (SILAC). For SILAC, one cell
line was grown with heavy amino acids to facilitate quantification of the
relative abundance of peptides between the two cell lysates. Spectral
counts, a measure of relative abundance, are the number of MS2 spectra
for a given protein. SILAC ratios, relative protein abundance between the
two cell lines, were normalized to the ratio for PARP1, the natural log (ln)
of each ratio was taken, and the results of two biological repeats were
averaged. The ln(ratios) for NuA4 proteins found in both repeats are
shown. See also Table S1.
Figure 4. PARP1 Forms Two Biochemically Distinct Complexes
with NuA4
(A) Immunoprecipitations were performed from 1 mg of total protein with the
indicated antibodies. Immunoprecipitated proteins were probed for PARP1,
EP400, or KAT5 by immunoblotting. The input sample contains 15 mg of total
protein.
(B andC) PARP1 activity (B), via 32P-NAD+ incorporation, and KAT5 activity (C),
via in vitro acetylation of histone H4, were measured in each immunoprecipi-
tated complex from MCF7 cell lysates (dark bars) and T47D cell lysates (light
bars). Representative data from three independent experiments is shown.
See also Figure S5.proteins immunoprecipitated from fraction 6 using the DAVID
bioinformatics platform (Huang et al., 2009b). The top enrich-
ment group consisted of eight members of the 16-member
NuA4 chromatin-modifying complex; this enrichment was
also obvious from visual inspection of the data. Further anal-
ysis of fraction 6 LC-MS/MS data identified 14 subunits of
the NuA4 complex that were highly enriched for fraction 6
when compared to fractions 2+3 and fractions 9+10 (Tables 1
and S1).
To test the hypothesis that NuA4 binding correlates with
PARP1 activity, relative levels of PARP1-binding partners were
compared between MCF7 total lysates and T47D total lysates
using stable isotope labeling by amino acids in culture (SILAC)
in combination with LC-MS/MS. PARP1 was immunoprecipi-
tated from MCF7 and T47D lysates after growing one cell line
in heavy amino acids, allowing for the relative quantification of
proteins identified in both cell lines. Nine subunits of the NuA4
complex were enriched in MCF7 PARP1 immunoprecipitations
from two biological repeats (Table 1). Thus, more NuA4 was in
complex with PARP1 in the high-activity line. These data are
consistent with a hypothesis that binding to NuA4 activates
PARP1 in the high-activity line.
To retest the PARP1-NuA4 interaction, reciprocal immuno-
precipitations were performed by immunoprecipitating either1812 Cell Reports 8, 1808–1818, September 25, 2014 ª2014 The Authe EP400 or KAT5(Tip60) subunits of the NuA4 complex and
measuring PARP1 by immunoblot (Figure 4A). PARP1 coimmu-
noprecipitated with both NuA4 subunits in both MCF7 and
T47D cell lysates. A small amount of PARP1 nonspecifically
bound to immunoglobulin G (IgG), but levels of PARP1 in the
EP400 and KAT5 immunoprecipitations were higher than in the
IgG control. In the reverse, EP400 coimmunoprecipitated with
both PARP1 and KAT5. A small amount of KAT5may coimmuno-
precipitate with PARP1 and EP400, but it was difficult to mea-
sure due to high background in the immunoblot. Next, we
measured the PARP activity of separately immunoprecipitated
PARP1, EP400, and KAT5 (Figure 4B). The highest PARP1 activ-
ity was observed for immunoprecipitated PARP1 fromMCF7 cell
lysates. Immunoprecipitated EP400 and KAT5 from MCF7 cell
lysates also demonstrated high PARP1 activity, confirming that
active PARP1 is in complex with NuA4. Immunoprecipitated
EP400 and KAT5 from T47D cell lysates also showed PARP1 ac-
tivity but at much lower levels than MCF7. This is consistent
with the lysate measurements and the sucrose gradient data
where a small peak of activity was seen at 700 kD for T47D.thors
Figure 5. Effects of PARP1 Activity on His-
tone Acetylation and Transcription
(A) Histone acetylation at the indicated positions in
MCF7 and T47D cells was measured by immu-
noblot after 0, 24, 48, and 72 hr of treatment with
10 mM niraparib. DMSO was used for the 0 time
point.
(B) Intensities of acetylated histones (marked with
arrows in A) were quantified in ImageJ and
normalized by actin. Normalized intensities were
plotted and fit with straight lines. The slope of
MCF7 H4K5,0.48 ± 0.03, is significantly different
from zero with R2 = 0.99 and p = 0.005. The other
fits are not significantly different from zero with p >
0.1. Fitting done in Prism.
(C) Hierarchical clustering of the 500 genes with
the largest SD across all 12 samples. Cell lines
were treated for 48 hr with DMSO or 10 mM ABT-
888 before transcript profiling. Values shown are
log2(expression level)
(D) Log2(expression levels) for E2F1 ± ABT-888 in
cell lines with low PARP activity (gray) and cell
lines with high PARP activity (black).
(E) E2F1 protein levels, determined by immuno-
blot, after 0, 24, 48 or 72 hr of 10 mM niraparib
treatment. Intensities of E2F1 were quantified in
ImageJ and normalized by actin. Error bars show
SE and n = 3.
See also Figure S6 and Table S2.These data indicate that NuA4 binds either active (from MCF7
cells) or inactive (from T47D cells) PARP1.
To test if active KAT5 was part of the active PARP1-
NuA4 complex, we measured acetyltransferase activity in the
PARP1, EP400, and KAT5 immunoprecipitations. Neither immu-
noprecipitated PARP1 or EP400 from MCF7 had acetyltrans-
ferase activity above the IgG control. Immunoprecipitated
PARP1 and EP400 from T47D cells showed a small amount of
activity. In both cell lines, immunoprecipitated KAT5 displayed
high acetyltransferase activity (Figure 4C). These data indicate
that KAT5 activity is not required for PARP1 activation in MCF7
cells.
To test if the NuA4-PARP1 complex is specific to cancer
cells, we repeated the immunoprecipitation and activity exper-Cell Reports 8, 1808–1818, Sepiments in retinal pigment epithelium
(RPE) cells. RPE cells are immortalized,
noncancer cells. They had low basal
PARP activity, comparable to T47D
cells (Figure S5A). In RPE cell lysates,
PARP1 with low activity immunoprecipi-
tated with both EP400 and KAT5, and
the acetyltransferase activity of the
PARP1 and EP400 immunoprecipita-
tions was at the limit of detection (Fig-
ures S5B–S5D). Together with our previ-
ous results, we concluded that the
PARP1-NuA4 complex is conserved
across cancer and noncancer cell lines;
however, the level of PARP1 activity
within the complex differs between celllines with higher activity observed in some cancer cell lines
such as MCF7.
Functional Consequences of the PARP1-NuA4
Interaction
Whereas acetylation was not essential for PARP1 activation,
PARP1 activity may affect histone acetylation by KAT5. We
measured the acetylation levels of a known target of KAT5, his-
tone H4 (Doyon and Co^te´, 2004). We treated cells for up to 72 hr
with the PARP1/PARP2 inhibitor niraparib and then blotted for
H4 acetylation at the K5, K8, or K12 positions (Figure 5A). No
differences were seen for T47D. For MCF7, a small but sig-
nificant decrease in acetylation of K5 was seen over 72 hr
(Figure 5B).tember 25, 2014 ª2014 The Authors 1813
Figure 6. NuA4 Components Are Required
for PARP1 Activity
Proteins were knocked down by siRNA in MCF7
cells.
(A) Representative image of RT-PCR on control
and siRNA-treated cells with quantification of the
results using ImageJ for background subtraction
and band intensity measurements. Error bars
show SE and n = 3.
(B) Protein levels in control and siRNA-treated
cells as measured by immunoblot and quantifica-
tion of the shown immunoblot using ImageJ.
(C) PARP1 activity measured by incubating lysates
with 32P-NAD+ for 30 min. Samples were normal-
ized by total protein concentrations and reported
as fraction of activity as compared to the lamin
A/lamin C siRNA control. Error bars show SE with
n = 4. A t test (Prism) comparing each siRNA to the
lamin A/lamin C control; ***p < 0.001; **p < 0.001–
0.01; *p < 0.01–0.05; not significant (ns), p > 0.05.NuA4 is also involved in gene regulation (Ginsburg et al., 2009;
Yamada, 2012), and we hypothesized that high basal PARP1 ac-
tivity of a PARP1-NuA4 complex affects transcription. We there-
fore measured global transcript levels via microarray in the
presence and absence of PARP inhibitors. First, we compared
MCF7 cells treated for 6 hr with DMSO, ABT-888, or olaparib,
two chemically distinct PARP1 inhibitors. Remarkably, given
the abundance and high basal activity of PARP1 in MCF7 cells,
we found no significant differences in transcript levels (Fig-
ure S6), suggesting that the PARP1-NuA4 complex is not a direct
regulator of transcription. To test for later transcriptional effects,
we repeated the microarray experiment with cells treated with
either ABT-888 or DMSO for 48 hr. We compared six cell lines,
three with high PARP activity (MCF7, KPL-1, and ZR7530)
and three with low PARP activity (T47D, SKBR3, and Hs578T).
Cell-line-specific differences dominated the differences in tran-
scription, and from a global perspective, PARP inhibitor treat-
ment caused little change in transcript levels as compared
to cell line differences. Unsupervised clustering placed drug-
treated and untreated next to each other for all lines (Figure 5C).
These data show that PARP1 inhibitors are not strong regula-
tors of global transcription. For a closer look at drug-induced
changes, we binned the data into two groups, high PARP activity
and low PARP activity, took the mean of each group, and ranked
the genes by the difference of the means (Table S2). Our top hit,
E2F1, is a transcription factor involved in cell cycle progression
that has been implicated in apoptosis and as a tumor suppressor
(Wang et al., 1999). E2F1 showed an increase in transcript levels
in low-PARP-activity cell lines and a decrease in high-activity cell
lines following drug treatment (Figure 5D). We next examined1814 Cell Reports 8, 1808–1818, September 25, 2014 ª2014 The AuthorsE2F1 protein levels in MCF7 and T47D
cells after 24, 48, and 72 hr of niraparib
treatment (Figure 5E). In both cell lines,
there was an initial increase in E2F1 pro-
tein followed by a gradual decline. T47D
cells (low PARP activity) showed consis-
tently higher levels of E2F1 than MCF7
cells, consistent with RNA levels. At72 hr of drug treatment, E2F1 protein level in T47D cells was
equivalent to the untreated level, whereas the level in MCF7 cells
was lower than the untreated level. We saw similar results in two
additional cell lines: KPL-1 (high activity) and SKBR3 (low activ-
ity; Figure S6). These data indicate a role for PARP activity in
regulating both RNA and protein levels for E2F1, and the magni-
tude of this regulation is different between the high- and low-
PARP-activity cell lines.
Chromatin-Remodeling Subunits of NuA4 Are Required
for High Basal PARP1 Activity
To test the hypothesis that NuA4 is required for activation of
PARP1, we knocked down multiple subunits of NuA4 in MCF7
cells and measured basal PARP1 activity in lysates. Using
siRNA, we knocked down the EP400, KAT5, RUVBL1, and
DMAP1 subunits of NuA4. Knockdown of EP400 showed the
most dramatic effect on PARP1 activity (Figure 6), reducing
PARP1 activity to a similar extent as knockdown of PARP1 itself.
RUVBL1 and DMAP1 knockdown also showed a reproducible
decrease in PARP1 activity, although not to the same low levels
as EP400 knockdown (Figure 6). This might be explained by
partial knockdown of the siRNA target. Knockdown of KAT5
had no significant effect on basal PARP1 activity in MCF7 cells.
Loss of PARP activity in the EP400, RUVBL1, and DMAP1
knockdowns could be explained by a concomitant loss of
PARP1. We examined PARP1 protein levels in all knockdowns
and found that NuA4 knockdowns did not significantly affect
PARP1 levels (data not shown). Lack of an effect of KAT5 knock-
down is consistent with the immunoprecipitation data, suggest-
ing that acetyltransferase activity is not required to activate
PARP1. Rather, subunits of NuA4 involved in chromatin re-
modeling, EP400, RUVBL1, and DMAP1 (Yamada, 2012), are
required for high basal PARP1 activity in MCF7 cells.
DISCUSSION
We found that PARP1 in cell lysate was distributed between at
least three complexes differing in native molecular weight and
interacting proteins. A low-molecular-weight fraction, which
comprised almost half of the total PARP1, moved on sucrose
gradients consistent with the expected mass of uncomplexed
PARP1. This fraction was basally inactive by ourmeans of detec-
tion and, interestingly, was not activated by nicked DNA, unlike
bacteria-expressed PARP1. We speculated that this uncom-
plexed fraction was somehow modified to prevent its activation
by nicked DNA. Two larger-molecular-weight pools of PARP1
(approximately 700 kD and >1 MD) contained most of the basal
and DNA-inducible activity. The >1 MD fraction is the least well
understood. It contained 35% of the PARP1 polypeptide and
had low levels of basal-specific activity but was highly inducible
by nicked DNA. Mass spectrometry has not yet provided a
consistent profile of PARP1-interacting proteins in this fraction,
which is clearly worthy of further study. We concentrated our
efforts on characterizing the fraction around 700 kD, which had
the highest basal activity per unit protein, the largest difference
between cell lines, and appeared to consist in part of a defined
complex between PARP1 and NuA4. The components of the
NuA4 complex have been previously identified in HeLa cells,
but PARP1 was not identified (Doyon et al., 2004). Based on
our results, PARP1 appears to be a dynamic member of the
NuA4 complex, whose interaction was likely disrupted by the
higher salt concentrations used in the HeLa cell purification.
Our primary focus was to understand the 10- to 60-fold differ-
ences in basal PARP1 activity found between breast cancer cell
lines. Surprisingly, the distribution of PARP1 protein on sucrose
gradients was similar between a high-activity cell line, MCF7,
and a low-activity cell line, T47D. The intermediate-sized frac-
tion, where PARP1 is complexed to NuA4, was hard to detect
by PARP1 immunoblot alone, but immunoprecipitation data
showed that this complex was present in both lines. Our data
so far showed that the distribution of PARP1 between com-
plexes was similar between cell lines and that the difference
was restricted to strong activation of PARP1 in MCF7 cells and
minimal activation (or possibly repression of activity) in T47D.
This differential activation was strongest in the NuA4 complex.
This complex was not limited to cancer cells and could be found
in a noncancer cell line, RPE, where it had biochemical charac-
teristics similar to the low-activity complex found in T47D cells.
Having identified the PARP1-NuA4 interaction, we began to
investigate the mechanism of PARP1 activation. Through siRNA
studies, we found that chromatin-remodeling components of
NuA4 were required for the activation of PARP1. However,
because NuA4 bound PARP1 in both high- and low-activity cell
lines, binding alone, though necessary, was not sufficient for
activation. In Drosophila, KAT5 is required for activation of
PARP1 upon heat shock (Petesch and Lis, 2012). Our experi-
ments indicate that KAT5 activity is not necessary for PARP1
activation. The data suggest that levels of NuA4, in particularCell ReEP400, may determine PARP1 activity. We examined transcript
levels of EP400 across cell lines and found no correlation with
PARP activity (Figure S7). Also, we saw no significant differences
in EP400 protein levels between MCF7 and T47D cell lysates,
and the amount of PARP1 that coimmunoprecipitates with
EP400 was similar between the two cell lines. Instead of the
amount or stoichiometry of the complex determining PARP1
activity, other enzymatic activities of NuA4 such as the ATPase
activity of EP400 may be required, or NuA4 may facilitate
the interaction of PARP1 with other activating factors. We are
continuing to explore the mechanistic details of PARP1 activa-
tion in these cell lines.
Though KAT5 activity was not required for PARP1 activation,
PARP1 may influence the histone acetylation functions of
KAT5. We saw a small effect of PARP1 activity on the levels
of acetylated histone H4(K5) in a high-PARP-activity cell line
and no effect in a low-activity cell line, suggesting that PARP1
may play a role in regulating histone acetylation. Whereas our
data are consistent with PARP1-regulating histone acetylation
through the NuA4 complex, we cannot rule out the involvement
of other acetyltransferases. H4(K5) acetylation is not specific to
NuA4, and other acetyltransferases could modify this position.
Both PARP1 and NuA4 have reported roles in transcription
(Doyon and Co^te´, 2004; Ji and Tulin, 2010; Krishnakumar and
Kraus, 2010a). We found no significant effect on transcription
after 6 hr of PARP inhibitor treatment, indicating that the
PARP1-NuA4 complex does not directly regulate transcription.
Surprisingly, we also found no strong global effect on transcrip-
tion after 48 hr of PARP inhibitor treatment. One possibility is that
high PARP1 activity primes cells to respond to other signals and
the effects of PARP1 inhibition on transcription would be larger
in the presence of another stimulus, as was seen in the case of
prostate cancer cells treated with testosterone (Schiewer et al.,
2012). By looking across multiple cell lines, we found PARP-
dependent regulation of E2F1. This is consistent with a previous
study showing PARP1 regulation of E2F1 transcription in fibro-
blasts (Simbulan-Rosenthal et al., 2003), andwe confirmed regu-
lation at the protein level. E2F1 is an important transcription
factor with potential roles as a tumor suppressor, and this regu-
latory interaction may be one reason why some cancers upregu-
late PARP1 activity.
We undertook a comparative analysis of breast cancer cell
lines in part to understand differential responses to PARP1 inhib-
itors in patients. We uncovered biochemistry of PARP1 suggest-
ing that PARP1 inhibitors may work through mechanisms other
than the currently proposed mechanisms of DNA repair. Cell
lines with both high and low basal PARP1 activity were similarly
unaffected by PARP1 inhibitors in culture, at least using standard
cytotoxicity assays (not shown). However, high basal PARP ac-
tivity might increase sensitivity to other drugs or combinations
with PARP inhibitors.
Finally, our results highlight the importance of looking at differ-
ences in enzymatic activity when comparing cell lines. Many
large-scale studies focus on transcript level differences between
cancer cell lines, but as our study highlights, potentially impor-
tant activity differences could be overlooked. Our study of basal
differences in PARP1 activation highlights a functional interac-
tion for PARP1 with a chromatin-remodeling complex and pavesports 8, 1808–1818, September 25, 2014 ª2014 The Authors 1815
the way for further elucidating non-stress-induced roles of
PARP1 in the nucleus and the impact of those roles on cancer
cell biology.
EXPERIMENTAL PROCEDURES
Cell Culture and Lysis
All cell lines (American Type Culture Collection) except KPL-1 and RPE were
grown in RPMI (Mediatech/Corning) supplemented with 10% fetal bovine
serum (FBS) (GIBCO). KPL-1 and RPE were grown in Dulbecco’s modified
Eagle’s medium/F12 (Mediatech/Corning) supplemented with 10% FBS. For
SILAC, cells were grown in RPMI without lysine or arginine (Caisson Labs)
supplemented with 10%FBS and either light (12C, 14N) or heavy (13C, 15N) argi-
nine and lysine (Sigma-Aldrich or Pierce). Cells harvested via trypsinization
were washed with PBS and frozen at 80C. Upon thawing, cells were lysed
in lysis buffer (50 mM Tris [pH 8], 150 mM NaCl, and 1% NP-40) for 30 min on
ice. Cell debris was pelleted at 4C and 21,000 3 g for 30 min. Lysate protein
concentration was determined with the Bio-Rad DC protein assay. For acety-
lation, E2F1, and DNA damage marker immunoblots, cells were lysed directly
in the tissue culture dish with 13 SDS loading buffer. Lysate was collected and
sonicated before boiling and loading the gel.
Antibodies
For immunoblotting, the following antibodies were used: anti-PARP1 (Tulip
Biolabs; 1051), anti-histone H4 and anti-acetyl-histone H4 (Lys5, Lys8, or
Lys12; Cell Signaling Technology; 8346), monoclonal anti-tubulin clone
DM1A (Sigma-Aldrich), monoclonal anti-actin clone AC-74 (Sigma-Aldrich),
anti-phospho ATM, ATR, CHK1, and CHK2 (Cell Signaling Technology;
9947), anti-DMAP1 (Bethyl Laboratories; A300-218A), anti-Tip60(KAT5) (Imge-
nex; IMG-6313A), anti-rabbit Dylight 800 (Thermo Scientific), anti-mouse
Dylight 680 (Thermo Scientific), anti-chicken IgY Dylight 800 (Thermo Scienti-
fic), anti-chicken IgY horseradish peroxidase (HRP; Abcam), anti-mouse HRP
(GEHealthcare), and anti-rabbit HRP (GEHealthcare). Proteins were visualized
using the ECL 2 kit (Thermo Scientific) for HRP detection or the Odyssey
(LI-COR Biosciences) for far-red (Dylight) fluorescent detection. For immuno-
precipitation, the following antibodies were used: anti-PARP (Cell Signaling
Technology; 46D11), anti-Tip60(KAT5) (Calbiochem; DR1041), and anti-
EP400 (Novus Biologicals; NB200-210). Anti-phospho histone H2Ax (Ser139;
Upstate; 05-636) was used for immunofluorescence followed by anti-mouse
Alexa 488 (Invitrogen).
Protein Purification
The tandem zinc finger domain of human APLF (residues 376–450; APLF-PAR-
binding domain [PBD]) was cloned into pET28a (Invitrogen) and expressed in
E. coli strain BL21(DE3) Rosetta pLysS (Novagen). Upon induction with isopro-
pyl b-D-1-thiogalactopyranoside, 500 mM ZnSO4 was added to the media.
Protein was expressed overnight at 16C. Cells were resuspended in 50 mM
Tris (pH 7.4), 1 M NaCl, 150 mM ZnSO4, 10% glycerol, 1% Tween, 5 mM
b-mercaptoethanol, and complete protease inhibitor cocktail (Roche) and
lysed using a cell disruptor. Cell debris was pelleted for 30 min at 138,000 3
g, and the supernatant was incubated with Ni-NTA resin (QIAGEN) at 4C for
2 hr. The nickel resin was washed with 20 mM Tris (pH 7.4), 1 M NaCl,
150 mM ZnSO4, 5 mM b-mercaptoethanol, and 20 mM imidazole and eluted
with 20 mM Tris (pH 7.4), 200 mM NaCl, 150 mM ZnSO4, 5 mM b-mercaptoe-
thanol, and 300mM imidazole. APLF-PBD was then gel filtered on a Sephacryl
S-100 column (GE Healthcare) using 50 mM Tris (pH 7.4), 200 mM NaCl,
100 mM ZnSO4, and 5 mM b-mercaptoethanol.
PARP1 and the catalytic fragment of PARG were purified as previously
described (Tan et al., 2012).
PAR Detection in Cellular Lysates
Monoclonal PAR antibody 10H (Tulip Biolabs) was conjugated to carboxylated
MagPlex beads (Luminex/Bio-rad). Briefly, 5 3 106 beads/ml were washed
and resuspended in coupling buffer (50 mM monobasic sodium phosphate
[pH 5.0]). 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride
(Oakwood Products) was added to a final concentration of 5 mg/ml and incu-1816 Cell Reports 8, 1808–1818, September 25, 2014 ª2014 The Aubated with the beads at room temperature for 20 min. Beads were washed
in coupling buffer, resuspended with 8 mg antibody in coupling buffer, and
incubated for 2 hr at room temperature. Conjugated beads (MagPlex-10H)
were washed and stored at 4C in PBS with 0.02% Tween, 0.1% BSA, and
0.05% azide.
To biotinylate APLF-PBD, 1.7 mg/ml purified protein was incubated with
0.5 mg/ml sulfo-NHS-LC-biotin (Invitrogen) for 1 hr at room temperature fol-
lowed by 1 hr at 4C. The reaction was quenched with 100 mM glycine.
For PAR detection, all lysates contained 1 mM ADP-HPD (Axxora; EMD Bio-
sciences). All dilutions and washes were done with PBS + 1% BSA. MagPlex-
10H beads (50 beads/ml) and lysate (50–200 ng total protein/ml) were incubated
together overnight at 4C. Beads were then washed, resuspended in 3 ng/ml
biotin-APLF-PBD, and incubated for 2 hr at room temperature. Next, beads
were washed, resuspended in 2 ng/ml conjugated streptavidin-R-phycoery-
thrin (Thermo Scientific), and incubated at room temperature for 30 min.
Finally, beads were washed, resuspended to a final concentration of 50
beads/ml, and analyzed on the FlexMap3D (Luminex). Free PAR, purified as
previously described (Tan et al., 2012), was used as a standard for
quantification.
32P PARP and PARG Activity Assays
For PARP activity, lysates (0.5–1mg total protein/ml) were incubatedwith 5 mCi
32P-NAD+ (PerkinElmer; 800 Ci/mmol 5 mCi/ml) and 1 mMADP-HPD in PBS or
lysis buffer at 30C. Reactions were quenched by adding trichloroacetic acid
(TCA; Sigma-Aldrich) to a final concentration of 10%. Quenched reactions
were filtered through nitrocellulose, prewet in PBS, and washed with 1%
TCA. 32P incorporation was quantified using a phosphor storage screen and
scanner (Bio-Rad). Ten micromolar ABT-888 (Selleck Chemicals) was added
as a control for PARP activity.
For PARG activity assays, 32P-labeled PAR-PARP1 was made through an
automodification reaction as described previously (Tan et al., 2012). Lysate
(0.5–1 mg total protein/ml) and 10 mM ABT-888 were added to the 32P-PAR-
PARP1 in PBS. The reactions were quenched and analyzed as for the 32P
PARP activity assay.
Immunoprecipitation
Whole-cell lysates or sucrose gradient fractions containing a protease inhibitor
cocktail (Roche) were incubated with antibody for 2 hr at 4C. Prewashed Affi-
Prep Protein A beads (Bio-Rad) were added and incubated for 1 hr at 4C with
the antibody/antigen complex. Beads were washed with 50 mM Tris (pH 8.0),
50 mM NaCl, 1 mM EGTA, and 1 mM MgCl2. SILAC samples were washed
with 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EGTA, and 1 mM MgCl2. For
SDS-PAGE analysis, proteins were eluted from the beads by boiling in sample
buffer, and immunoblots were performed using the LI-COR Biosciences Quick
Western Detection Kit. Activity assays were performed directly on beads.
Sucrose Gradient Fractionation
Sucrose gradients (5%–40%w/w) were poured as step gradients of five equal
volume steps in 50 mM Tris (pH 8.0), 50 mM NaCl, 1 mM EGTA, and 1 mM
MgCl2 and allowed to diffuse overnight into continuous gradients. Gradients
were spun at 4C and 237,000 3 g for 4 hr in an SW55Ti rotor (Beckman
Coulter Genomics). Gradients were fractionated from the top by pipetting. A
standard containing thyroglobulin, catalase, aldolase, and BSA was run in
parallel.
LC-MS/MS Analysis
PARP1 immunoprecipitation samples from SILAC experiments were reduced
in 20 mM dithiothreitol (DTT; Sigma-Aldrich), alkylated with 100 mM iodoace-
tamide (Thermo Scientific), and separated on SDS-PAGE. Each lane was cut
into six pieces and digested with trypsin (Promega). Sucrose gradient
PARP1 immunoprecipitation samples were eluted from beads with 8 M urea
in 50 mM Tris (pH 8.0), reduced in 20 mM DTT, alkylated with 40 mM iodoace-
tamide, quenched with 10 mM DTT, diluted to less than 1 M urea with 50 mM
Tris (pH 8.0), and digested with trypsin (Promega). Samples were run on a
Thermo Fisher Q Exactive coupled with Exigent LC system (AB Sciex) over a
1 hr gradient. Peptide identification and quantification was performed with
MaxQuant v1.3.05 (Cox et al., 2009).thors
KAT5 In Vitro Activity Assay
Beads from KAT5 immunoprecipitations were mixed with 0.2 mg/ml histone
H4 peptide (SignalChem) and 10 mMacetyl-coenzyme A (EMDMillipore), incu-
bated for 30 min at 30C, and spotted onto nitrocellulose. The membrane was
blocked and probed with anti-acetyl H4(K8) (Cell Signaling Technology). A
far-red fluorescent secondary antibody was used for imaging on the Odyssey
(LI-COR Biosciences). Background subtraction and quantification was done
with the ImageJ MBF plugin suite (http://rsb.info.nih.gov/ij/plugins/mbf/
index.html).
RNAi
Cells were transfected with siRNA using either Lipofectamine 2000 or RNAi-
Max (Invitrogen) according to the manufacturer’s protocol. RNAi was done
with a double transfection protocol over 7 days total. Cells were allowed
to recover for 3 days after the first transfection, retransfected, and then
allowed to grow for an additional 3 days. All siRNAswere ordered from Thermo
Scientific, and the following siRNAs were used: PARP1 ON-TARGETplus
(GAUUUCAUCUGGUGUGAUA or CCAAUAGGCUUAAUCCUGU), EP400 siG
ENOME siRNA SMARTpool, KAT5 siGENOME siRNA SMARTpool, RUVBL1
siGENOME siRNA SMARTpool, and DMAP1 siGENOME siRNA SMARTpool.
RNAi efficiency was tested via RT-PCR or immunoblot. Total RNA was ex-
tracted from cells with the QIAGEN RNeasy kit, and RT-PCR was done with
the One-step RT-PCR kit (QIAGEN) with the following primer pairs: PARP1,
GCCCTAAAGGCTCAGAACGA and AGCTTCCCGAGAGTCAGGAT; EP400,
TCCCAGCAGCAACCATTTCA and ATTCCTCCTTGTGCGGTCG; KAT5, AGG
GGGAGATAATCGAGGGC and CACCTTCCGTTTCGTTGAGC; RUVBL1, TG
GTTTTCCACGCTGGTTTT and CTCCTTTATTCGCAGCCCAATG; DMAP1,
CAAGGCCCCCAAAAAGAAGC and GCTTTCTCGAATTGGGCGTG; and
PARP2, AGGTCATGGGCCAGCAAAAG and ACGGAGTCCAAAGTCATGCG.
Transcriptional Profiling
Cells were treated with DMSO, olaparib, or ABT-888 (Selleck Chemicals) for 6
or 48 hr and harvested via trypsinization. Total RNA was extracted using the
QIAGEN RNeasy Plus kit. Samples were submitted to the Boston Children’s
Hospital Microarray Core Facility for transcriptional profiling using Illumina
HT-12 beadchips. Initial data analysis including normalization and background
subtraction was performed with the Illumina GenomeStudio software pack-
age. The quantile-background subtracted data were used for further analysis
using the R platform.
ACCESSION NUMBERS
Transcript-profiling data have been deposited to the NCBI Gene Expression
Omnibus and are accessible under accession numbers GSE58844 and
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